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Short wavelengths of ultraviolet (UV) light are clearly
harmful in systemic lupus erythematosus (SLE), but the
action of long UV wavelengths in SLE is more enigmatic.
In a series of animal and human studies, long-wavelength
UV radiation, i.e., radiation in the ultraviolet-A1 (UVA1)
range (340–400 nm), has proven effective in the treatment
of SLE. Disease amelioration and a marked decrease in
mortality followed ultraviolet-A (UVA) radiation (320–
400 nm) of the New Zealand White/New Zealand Black
mouse model of lupus. A follow-up study in the same
animal suggested that the longer wavelengths (UVA1,
340–400 nm) in the UVA wave band were primarily
responsible. There followed four human studies. The first
three of these provided data indicating that low-dose
UVA1 radiation significantly reduced constitutional
THE TOXICITY OF ULTRAVIOLET RADIATION IN
SYSTEMIC LUPUS ERYTHEMATOSUS
Sensitivity to ultraviolet (UV) radiation is characteristic in systemic lupus
erythematosus (SLE) and the systemic expression of photosensitivity is
unique to this disease. SLE photosensitivity has long been attributed
to the UV wavelengths below 320 nm (Kochevar, 1985), and abnormal
morphologic and histologic responses were generated with wavelengths
up to 320 nm (Epstein et al, 1965). For example, erythema has been
produced by exposing SLE patients to wavelengths up to 330 nm
(Cripps and Rankin, 1973), and while repeated exposure of SLE
patients to monochromatic light of 300 nm generated lesions, exposure
to radiation 340 nm or above did not (Freeman et al, 1969). Additionally,
single ultraviolet-B (UVB) exposures induced prolonged erythema in
62.5% of SLE patients (Wolska et al, 1989); ultraviolet-C (UVC) in vitro
degraded DNA in SLE peripheral blood lymphocytes 4-fold over that
in normal peripheral blood lymphocytes (Compton et al, 1984); and
finally, UVC but not ultraviolet-A (UVA) was toxic to fibroblasts in
MRL/Mp-lpr/lpr lupus mice but not in BALB/C mice (Furukawa
et al, 1989).
In more recent studies, wavelengths in the UVA range, if inclusive
of the shorter portion of the UVA spectrum, also induced photosensitive
reactions. For example, high intensity (100 J per cm2) UVA radiation
from 330 to 460 nm produced lesions in approximately half of SLE
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symptoms, joint pain, rashes, and the systemic lupus
activity measures, a validated gauge of disease activity in
SLE. The fourth human study showed that the therapeutic
action of low-dose UVA1 action persisted or progressed
long term, a period averaging 3.4 y. UVA1 effects on
DNA repair, cell-mediated immunosuppression, tumor
necrosis factor alpha release, and apoptosis contrast
markedly with those of ultraviolet B (UVB, 280–320 nm)
radiation and afford a possible basis for the salutary action
of this modality of treatment. The unique features of
UVA1 wavelengths may be suited to further therapeutic
use, not only in SLE but also in other immunologic
disorders. Key words: light therapy/photosensitivity/systemic
lupus erythematosus/ultraviolet A1. Journal of Investigative
Dermatology Symposium Proceedings 4:79–84, 1999
patients who responded adversely to UVB radiation (Lehmann et al,
1990), and UVA exposure of photosensitive SLE patients to wavelengths
from 320 to 340 nm in doses of 4.2–25.2 J per cm2 induced erythema,
that lasted 2 wk in some (Nived et al, 1993); cutaneous lupus
erythematosus was exacerbated by the UVA wavelengths from a
photocopier (Klein et al, 1995); exposure to a mixture of UVB/UVA
irradiation in a tanning salon provoked a response in an SLE patient
(Stern and Docken, 1986); and lupus erythematosus (LE) like lesions
were induced in 20 of 24 photosensitive SLE patients using wavelengths
of 330–440 nm and in four patients using visible light (van Weelden
et al, 1989). Fibroblasts from patients with SLE were more sensitive to
UVC (254 nm) and UVA (320–400 nm) radiation than were normal
cells (Zamansky et al, 1985), although the repair mechanisms appeared
to remain intact (Zamansky, 1986). Lymphocytes from SLE patients
were more sensitive to UVA1 radiation in the 360–400 nm range,
related to the presence of clastogenic factor in the serum, a sensitivity
due possibly to the generation of reactive oxygen species (Emerit and
Michelson, 1981). The data from the three studies is summarized
in Table I.
When combined with psoralens, UVA forms photoadducts in DNA,
which are useful in slowing down DNA replication and mitosis and
thereby useful in diseases such as psoriasis and vitiligo. Because psoralen
and UVA (PUVA) make the photoproduct antigenic by altering DNA
structure (Zarebska et al, 1978), the concern arose that PUVA would
aggravate SLE. Several case reports provided evidence that this was so
(Dowdy et al, 1989; McGrath et al, 1990); however, the further concern
that PUVA might induce the disease proved to be unfounded (McGrath
et al, 1990).
Complicating the entire issue of photosensitivity in SLE are poly-
morphous light eruptions (PLE) and drug-induced photosensitivity.
An overlap of photosensitivity in SLE with that of PLE became evident
after a study of 67 LE patients with a positive UV provocative test
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Figure 1. Survival of New Zealand Black/New Zealand White F1
mice exposed or not exposed to ultraviolet-A radiation. u, exposed;
u, not exposed.
showed that most had a PLE-like histology on biopsy, and that in over
half these patients PLE coexisted with LE (Hasan et al, 1997). Moreover,
PLE usually starts years before the systemic and cutaneous LE, and
possibly predisposes to it (Nyberg et al, 1997). Wavelengths in the
UVA range most often generate the drug-induced photosensitivities,
which are becoming more common as the list of frequently used
photosensitizing drugs, now well over 100, continues to grow.
THE SALUBRIOUS ACTION OF UV RADIATION IN SLE
Despite the toxicity of short wavelength radiation in SLE, the relatively
benign effects of UVA radiation prompted a study of UVA wavelength
action in the New Zealand Black/New Zealand White F1 hybrid
mouse model of SLE (McGrath et al, 1987). Unexpectedly, low-dose
(35 kJ per m2) daily exposure for 32 wk to predominately UVA-
emitting black lamps eliminated mortality and significantly decreased
autoimmunity in these mice over an 8-mo period during which 60%
of the nonirradiated control mice died (Fig 1), in line with an
established mortality rate for these animals (Dixon, 1985). In a follow-
up study using the same animals exposed for a longer time to cool
white fluorescent lamps, filtered to transmit only visible light and low
levels of UV radiation, it appeared that the UVA1 wavelengths were
responsible for the benefits observed (Rihner and McGrath, 1992).
These observations generated a series of four human studies, the
first two open (McGrath et al, 1994a; McGrath, 1994), the third
double-blinded and placebo controlled (McGrath et al, 1996), and the
fourth long term (Molina and McGrath, 1997). In the aggregate, these
human studies presented a picture as encouraging as that drawn from
the animal studies. The lamps used for the human studies, TL/10R
(Philips Company, Eindhoven, The Netherlands), primarily emitted
UVA1 radiation and only low levels (0.06% and 0.03%) of UVB and
UVA2 (UVA2, 320–340 nm) wavelengths that were present in the
black lamp emissions used in the first mouse study.
In the first of the two open human studies (McGrath et al, 1994a),
low-dose, 5-d-a-week TL/10R lamp irradiation of 15 SLE patients
significantly (p , 0.05) decreased clinical disease activity scores
(p , 0.0005): fatigue, joint pain, fever, malaise, and morning stiffness
each decreased significantly (p , 0.05). The efficacy and apparent
safety of UVA1 radiation in this seminal study prompted the second
open human study (McGrath et al, 1994b), which differed from the
first only in that the remaining vestiges of UVB and UVA2 wavelengths
were eliminated from the TL/10R lamp source with UVASUN filters
(Mutzhas, Munich, Germany). Clinical responsiveness increased (Fig 2),
SSA antibody titers and photosensitivity decreased; in one patient,
striking amelioration of a severe annular subacute cutaneous lupus
erythematosus rash occurred.
Following the open studies, we undertook a prospective, placebo-
controlled, double-blind, cross-over study comparing UVA1 irradiation
with visible light (McGrath et al, 1996). In this trial we substantiated
Figure 2. Second open human study (UVASUN filters added). Changes
in 10 specific clinical disease activity scores following 3 wk of 5-d-a-week
UVA1 radiation averaging 60 kJ per m2 per d.
Figure 3. SLAM scores. During the first 6-wk, double-blind, 5-d-a-week
irradiation phase of the study, Group A (d) patients received UVA1 (—) for
3 wk and were then crossed over to receive placebo (- - - -) for 3 wk. Group
B (n) patients received placebo irradiation for the first 3 wk and were then
crossed over to receive UVA1 for 3 wk. During the unblinded phase of the
study, starting at week 6, all patients received UVA1 irradiation 3 d a week:
*p . 0.05; **p , 0.01. (Reprinted with permission from Lupus, Stockton Press.)
that low-dose UVA1 irradiation emitted from UVASUN-filtered TL/
10R lamps effected clinical and serologic benefits in patients with SLE.
Specifically, the treatment significantly reduced the systemic lupus
activity measures (SLAM) and ameliorated fatigue, arthritis, mouth
ulcers, photosensitivity, and acute and subacute but not discoid
cutaneous lupus rashes (Fig 3). The data from the three studies is
summarized in Table 1.
We followed six patients for an average of 3.4 y and observed that
twice-a-week therapy maintained or increased the gains initially
obtained and that discontinuance of therapy brought relapses (Molina
and McGrath, 1997) (Fig 4). One of our long-term patients, a woman
with fair skin and red hair whose severe photosensitivity had been
virtually eliminated with UVA1 therapy, developed two lentigos after
5 y of therapy, during which time she had intentionally increased her
natural sun exposure. Biopsy evidence of dysplastic changes in these
lentigos, although benign, prompted the discontinuance of therapy.
Fortunately, by this time, the patient appeared to have gone into
remission.
Although UV-sensitive and SSA Å patients responded slightly better
to the UVA1 therapy than did nonphotosensitive patients, the difference
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Figure 4. Long-term UVA1 radiation therapy. Depicted are the changes
in disease activity as measured by the SLAM in six patients treated with low-
dose UVA1 radiation 3–5 times a week for 12 wk and then 1–3 times a week
for an average of 3.4 y. *p , 0.05.
was not significant. These study patients tolerated plaquenil, prednisone,
and NSAID but in our most recent studies, drugs such as thiazides and
calcium channel blockers, known to be photosensitizers for patients
with subacute cutaneous lupus erythematosus (SCLE), occasionally
resulted in rashes. As mentioned above, because drug-induced photo-
sensitivity is becoming more common, patients taking such drugs are
observed closely for any sign of drug-induced photosensitivity.
ACCOUNTING FOR THE DIFFERENCES IN THE
PROPERTIES OF DIFFERENT UV WAVELENGTHS
The UV spectrum, comprising UVA, UVB, UVC, and vacuum UV,
was only recently subdivided. The UVA band was separated into UVA2
(from 320 to 340 nm) and UVA1 (from 340 to 400 nm). This division
was recommended, at least in part, because it had become evident that
UVA2 was, in effect, an extension of UVB (Kochevar et al, 1992) and
that UVA1, as is evident from our own studies, had its own set of
properties, some of which overlapped with those of visible light
(Brainard et al, 1992). For this reason, the 340 nm demarcation became
more useful than 320 nm for separating UV wavelengths according to
their photobiologic properties and their effect in SLE.
UVB encompasses wavelengths absorbed chiefly by nucleic acids
and proteins in the epidermis (Setlow, 1974). These wavelengths
promote DNA pyrimidine dimer formation (Sutherland, 1996), release
tumor necrosis factor (Skov et al, 1998), trigger translocation of nuclear
antigens to cell surfaces (Golan et al, 1992), and suppress cell-mediated
immunity (Kripke and Applegate, 1991); all these actions have the
potential to exacerbate disease activity in SLE.
In contrast, UVA1 photons bypass nucleic acids (Sutherland and
Griffen, 1981), penetrating more deeply than those of UVB and
reaching putative non-DNA endogenous chromophores in the dermis
and its circulating blood and lymph cells (Bruls et al, 1984). Although
capable of engendering their own brand of DNA damage, UVA1
photons also give rise to photoreactivation (Sutherland and Bennett,
1995), a light-dependent mechanism for the repair of DNA, the major
autoimmune antigen in SLE (Tan and Miescher, 1971). These photons
also inhibit the release of tumor necrosis factor-α (TNF-α; Skov et al,
1998), thus inhibiting UVB-generated increases in vascular permeability
factor (Longuet-Perret et al, 1998), a TNF-α-generated mediator of
solar-induced erythema. Broadband UVA photons do not suppress
cell-mediated immunity (Aubin and Kripke, 1992), which is already
suppressed in SLE (Horowitz, 1972), and, in fact, UVA photons inhibit
UVB radiation- or cis-urocanic acid-induced suppression of cell-
mediated immunity (Reeve et al, 1998). Furthermore, wavelengths in
the UVA1 range actually enhance cell-mediated immunity (McGrath
et al, 1987; Hager et al, 1989), due, at least in part, to their capacity
to increase numbers of immunoenhancing CD1a1 dendritic epidermal
cells in irradiated skin (Krutman et al, 1992).
UVA1’S ROLE IN TRANSLOCATION AND APOPTOSIS
In determining pathways by which UVA1 radiation may elicit benefits,
the responsiveness of SCLE is telling. This disorder, characterized by
the presence of high levels of circulating precipitating antibodies to
SSA1 and, as determined by fluorescence studies, epidermal deposition
of Ig (Nieboer et al, 1988),1 presumably anti-SSA, resolves during
UVA1 radiation treatment, which decreases levels of anti-SSA antibodies
(McGrath, 1994).
We speculate that antibodies to SSA and some other nuclear antigens
are pivotal in converting translocation, a normally physiologic process,
into a pathologic one. During exposure to UVB radiation (Golan et al,
1992; Jones, 1992) or to estrogens (Furukawa et al, 1988), viruses
(Baboonian et al, 1989), or other cell stresses (Kaufmann, 1990), the
nuclear antigens SSA, SSB, RNP, and Sm translocate from the nucleus
to the cytoplasm and from there to the cell membrane, apparently as
an early stage of an apoptotic process that manifests in the formation
of apoptotic blebs on the cell surface (Rosen et al, 1995). In SLE, if
these antigens are bound after translocation to the cell surface by
their respective autoimmune antibodies, they can either activate
complement-dependent, antibody-dependent cellular cytotoxicity
(ADCC)-induced cell necrosis (Norris et al, 1984), or facilitate passage
of the antigen-antibody complexes into the cell (Lee et al, 1989). Cell
necrosis releases immunogenic autoantigens, inflammatory mediators,
and perhaps viruses (Rosen et al, 1995) into the circulation, while
entry of antigen-antibody into the cell presumably leads to cell
dysfunction. UVA1 radiation has the potential to offset both of these
eventualities, first, through initiation of ‘‘immediate’’ apoptosis (Godar,
1996) that preempts completion of translocation, and second, by
reducing interleukin-12 (IL-12), a key mediator of ADCC.
The first of these, ‘‘immediate’’ apoptosis, is triggered by the well-
established capacity of UVA1 photons to generate the reactive oxygen
species singlet oxygen (Godar, 1999). By depolarizing the mitochondrial
membrane, singlet oxygen interrupts the progression to cell apoptosis
that is ordinarily initiated by the assembly of death-signaling complexes
such as Fas/Fas ligand at the cell surface. Because immediate apoptosis
is rapid, it has the capacity to come to completion prior to the
completion of translocation. A recent report that Fas ligand/Fas receptor
interactions in SLE are inhibited by specific antibodies (Suzuki et al,
1998) suggests UVA1-induced immediate apoptosis exerts another
benefit: that UVA1 may be bringing about apoptosis where none
would have otherwise occurred. Several other reports describe defects
in the apoptotic process in humans with SLE (Cheng et al, 1994;
Rieux-Laucet et al, 1995), strengthening the possibility that singlet-
oxygen-induced immediate apoptosis is beneficial in SLE. We tested
the action of UVA1 radiation on an indirect measure of apoptosis, the
release of caspase from peripheral blood lymphocytes, and found
significant increases in SLE patients and normal subjects 24 h after a
20-min total body UVA1 exposure (unpublished observation).
As for IL-12, this cytokine is a central mediator of ADCC (Trincheri,
1995) and decreases in its level would dampen cell lysis in SLE.
Interestingly, UVA1 releases IL-10 (Krutmann et al, 1992), a cytokine
that decreases IL-12 levels (de Waal et al, 1993). In addition, whereas
Th2-like, cytokine-directed eosinophils produce IL-12 (Grewe et al,
1998), UVA1 irradiation of patients with atopic dermatitis decreases
levels of eosinophils (Krutmann et al, 1998) – observations further
suggesting that UVA1 radiation can decrease IL-12 levels. Our prelimin-
ary studies indicate that low-dose UVA1 irradiation decreased IL-12
levels in normal subjects and SLE patients alike. Accordingly, UVA1’s
healing action in SCLE may be due to a dampening of cell necrosis
1Lee LA, Roberts CM, Frank B, McCubbin V, Rice D, Reichlin M:
Autoantibody markers of cutaneous lupus erythematosus. J Invest Dermatol
100:573, 1993 (abstr.)
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Table I. The 11 columns depict demographic data, a brief antibody profile, the global clinical score, and the scores for joint pain
and fatigue of the 51 patients studied. A blank row separates each of the three groups, made up, respectively, of the 15 patients
from the first study, the 10 from the second, and the 26 from the third. The scores in the third study are based on a wider scale
(SLAM) than are those in the first two studies. Because the three studies were completed 8, 6, and 4 y ago, some patients were
lost to follow-up. (Two patients added more recently are listed at the end.)
Clin. score Fatigue Joint pain
Name Age Sex Race Ab to SSA Ab to DNA ANA before/after before/after before/after Photoa
HB 55 F A A 1 2 1 12→2 2→0 1→0 %
PB 53 F C 2 1 1 19→17 3→3 3→2 %
GV 59 F A A 2 1 1 18→20 2→3 2→1 %
AH 32 F A A 1 1 1 14→19 2→1 1→0 %
DP 52 M C 2 2 2 Dropped out 2→3 2→3 2
EK 57 F C 2 2 2 18→10 3→1 2→1 2
DM 30 F C 2 2 2 20→12 3→2 2→1 2
CC 30 F C 2 2 2 18→12 3→2 1→1 1
AP 49 F C 1 2 1 13→11 2→2 2→1 2
VM 39 F A A 1 2 1 13→5 2→0 2→1 2
HL 58 M C 1 1 1 12→6 2→1 2→1 2
CW 41 F C 2 2 2 19→14 3→2 2→2 1
JL 56 F A A 1 1 1 19→14 2→1 2→1 2
DC 31 F C 1 1 1 9→5 2→1 0→0 1
JW 59 F C 2 1 1 17→8 3→1 2→2 1
DL 35 F C 2 2 1 16→7 2→1 2→1 1
AA 35 F A A 2 2 1 20→14 3→2 3→2 1
CG 35 F C 1 2 1 8→4 1→1 0→0 1
JD 60 F C 2 1 1 24→11 3→2 3→1 2
SS 30 F C 1 2 1 21→20 3→3 3→2 1
ML 35 F A A 2 2 _ 6→2 0→0 3→1 1
BT 58 F C 1 2 1 19→10 2→1 2→1 1
DS 28 F C 1 2 15→5 2→1 1→0 1
DN 47 F A A 1 16→11 2→2 2→2 1
MM 68 M C 2 2 1 8→9 2→2 1→1 1
LA 36 F C 1 7→3 4→1 3→5 1
LC 34 F A A 1 1 1 8→4 6→1 5→1 2
SH 36 F C 1 2 1 12→6 6→4 0.5 2
PH 43 F A A 2 2 1 6→8 4→2 4→1 2
CH 33 F C 2 2 1 19→20 6→5 5→5 1
DM 51 F CC 2 2 1 8→6 0→0 0→0 2
BR 44 F C 2 2 2 6→2 6.5→4 6→3 1
KR 48 F C 1 2 1 15→11 8→4 5.5→3 2
MT 26 F C 2 1 1 14→4 2.5→2 2.5→3 1
NV 47 F C 2 2 1 7→7 4.5→7 4→8 1
WM 53 F C 2 1 5→3 7→1 8→1 1
TL 33 F A A 1 1 1 5→5 8→4 5→2 1
JF 33 F A A 2 1 12→6 8→2 6→4 1
SV 36 F C 2 2 1 9→7 4.5→5 4→4 1
DSp 23 F C 2 1 1 9→4 8→3 6.5→3 2
KK 24 F C 2 2 1 7→6 5→6 6.6→4 1
LD 30 F A A 2 2 1 4→2 8→0.5 8→0.5 1
EG 38 F C 2 2 2 7→8 5→8 3→9 1
RE 34 F A A 2 2 1 8→7 7→5 5→2 2
TP 32 F C 1 2 1 7→7 7→3 6.5→2 1
DSa 38 F C 2 2 2 6→6 6→8 7→7 1
AF 66 F C 2 2 2 7→4 10→4 6.5→6
BA 59 F C 2 2 2 10→3 7.5→4 4→4 2
NL 50 F A A 2 2 1 11→13 8.5→7 7→7 1
MF 38 F C 2 2 2 8→8 7→3 8→4
BM 53 F C 1 1 1 19→6 6→1 6→2 1
aPhotosensitivity.
by three means: a decrease in levels of precipitating SSA antibody,
activation of immediate apoptosis, and a reduction in IL-12 levels.
THE ENERGY FACTOR
It is intriguing that whereas the predominant result of UVA1 photon
energy delivery in humans is the transfer of this energy to the system
through the reactive oxygen species singlet oxygen, the most frequent
and rewarding effect of UVA1 radiation in the SLE patient is increased
energy, or conversely, decreased fatigue, as though a deficiency in SLE
patients was being replaced by this oxidative source. Put another way,
singlet oxygen that is ordinarily generated endogenously as a reactive
oxygen species from the respiratory chain in mitochondria, when
introduced exogenously through UVA1 photon bombardment, is
beneficial to SLE patients who otherwise avoid exposure to all UV
sources because of short UV wavelength toxicity.
UNMASKING UVA1 PROPERTIES
Since the discovery of the photoelectric effect nearly a century ago,
we have known but sometimes forget that the properties of different
wavelengths within the UV spectrum differ qualitatively. The con-
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trasting actions of UVB and UVA1 radiation in SLE underscore this.
The singular nature of the UVA1 band of wavelengths is apparent not
only in its actions in SLE but now in its effectiveness in the treatment
of atopic dermatitis (Krutmann et al, 1992), localized scleroderma
(Kerscher et al, 1995), urticaria pigmentosa (Stege et al, 1996), and
generalized granuloma annulare (Muchenberger et al, 1997).
The properties of UVA1 wavelengths are in contrast also with those
of UVA2 (Hager et al, 1989; Sutherland et al, 1991; Skov et al, 1998);
however, this discordance has been underappreciated because almost
all studies of wavelengths in the UVA range to date have been done
with broadband UVA, 320–380 nm, while actions of the isolated
UVA2 and UVA1 wavelength bands have received little attention.
Whenever a UVA action is reported to differ from that of UVB, it is
generally assumed that all wavelengths in the UVA wave band are
responsible. The possibility that the actions of one may obscure those
of the other has been ignored. For example, when it was found
that UVB-generated cis-urocanic acid’s immunosuppressive activity
(Webber et al, 1997; Reeve et al, 1998) was inhibited by UVA,
investigators assumed that the entire UVA spectrum was responsible.
That UVA2 is virtually an extension of UVB (Kochevar, 1992) was
not taken into account, nor was the fact that UVA2 should have
generated immunosuppression and did not, which certainly implicated
UVA1 as inhibitory. In fact, it turns out that when UVA1 irradiation
is isolated, it actually enhances cell-mediated immunity, affirming a
discordance with UVA2 and the potential to offset UVA2-induced
immunosuppression.
To illustrate further, broadband UVA wavelengths have been reported
to have no effect on TNF-α release (Kock et al, 1990; Skov et al,
1998), but since UVA1 irradiation inhibits TNF-α (Skov, 1998) release,
UVA2 is presumably masking this inhibition. In fact UVA2, like UVB,
promotes TNF-α release. As another example, UVA wavelengths shift
the DNA repair/damage ratio toward repair, but it is actually the
UVA1 wavelengths above 360 nm – those well into the UVA1 range –
that account for this shift (Sutherland et al, 1991). Shorter UVA
wavelengths, i.e., those in the UVA2 range, foster damage as much as
or more than they generate repair.
Studies to isolate these disparate properties of UVA1 and UVA2 are
needed. It’s even quite possible, for instance, that UVA’s failure to
trigger the process of translocation is due to inhibition by UVA1,
inasmuch as UVA2 should, like UVB, generate translocation. Similarly,
UVA photons, which cannot promote tyrosine phosphorylation as
UVC and UVB photons readily do (Schieven et al, 1993), may fail to
do so because of an inhibitory action by UVA1 wavelengths.
Our interest in these divergent actions of UVA1 and UVA2, some
demonstrated and some hypothetical, is that they hint at properties of
UVA1 that may account for its salutary action in SLE. Thus, in SLE,
the damaged DNA molecule is immunogenic (Tan and Miescher,
1971); TNF-α accelerates disease (Brennan et al, 1989); translocation,
which is increased in SLE (Golan et al, 1992), has the potential to
induce cell necrosis; and lymphocyte tyrosine phosphorylation, which
is increased in SLE (Matache et al, 1996), enhances immunoreactivity.
A UVA1-induced inhibition or overriding of these phenomena could
account for some of the UVA-induced benefits observed.
The counterbalancing actions of different bands of UV radiation,
including those of UVA1 and UVA2, not only explain their different
effects in SLE but reflect the balances that manifest in natural sunlight
and that are important for terrestrial life and health. We envision
that UVA1 wavelengths will eventually prove useful for strategically
tipping photobiologic balances, not only in SLE but also in other
diseases.
PROSPECTS
This is now the seventh year of UVA1 radiation treatment of human
subjects with SLE. The gains patients undergoing this therapy have
made are rewarding, the simplicity and lack of toxicity of the therapy
encouraging. We are presently investigating changes in dermal and
circulating cells and in humoral factors generated by these cells with
UVA1 irradiation. We also are evaluating means (i.e., duration and
intensity of exposure, addition or deletion of medications) to optimize
its effectiveness.
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